Page Title
Clinical Trial Finder
Observational Closed to Enrollment
A study of strength and muscle development to assess nutrition and lung function in people with CF ages 18 and older. (STRONG-CF)
This observational study will look at physical measurements, including body mass index and body composition, and compare them to bone density scans. This study includes measurements of arm circumference, hand-grip strength, distance walked in 6 minutes, and lung function.
The results of this study will provide information about the nutrition and body composition of people living with CF. This study will also help researchers understand better what contributes to malnutrition in some adults with advanced lung disease. This information will provide a baseline - or starting point - for future studies.This study may require blood draws, lung function tests, nutritional assessments, and/or other measurements.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
The participants for Cohort 1 must have an FEV1 of 60% or lower at the screening visit. The participants for Cohort 2 must have an FEV1 of 60% or greater at the screening visit.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
12 months -
Number of Study Visits:
5
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
-
Study Drugs:
N/A
Study Sites
-
Closed to Enrollment
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85719
-
Closed to Enrollment
Arkansas
University of Arkansas for Medical Sciences, Little Rock, AR 72205
-
Closed to Enrollment
Georgia
Emory University, Atlanta, GA 30324
-
Closed to Enrollment
Illinois
Northwestern University, Chicago, IL 60611
-
Closed to Enrollment
Iowa
University of Iowa, Iowa City, IA 52242
-
Closed to Enrollment
Kentucky
University of Kentucky, Lexington, KY 40536
-
Closed to Enrollment
Louisiana
Tulane University, Metairie, LA 70006
-
Closed to Enrollment
Maryland
Johns Hopkins University, Baltimore, MD 21205
-
Closed to Enrollment
Massachusetts
Massachusetts General Hospital, Boston, MA 02114
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Boston, MA 02115
-
Closed to Enrollment
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55455
-
Closed to Enrollment
Missouri
Washington University School of Medicine, St. Louis, MO 63110
-
Closed to Enrollment
New Jersey
Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ 08903
-
Closed to Enrollment
New York
New York Medical College at Westchester Medical Center, Valhalla, NY 10595
-
Closed to Enrollment
New York
Long Island Jewish Medical Center, New Hyde Park, NY 11042
-
Closed to Enrollment
Ohio
University of Cincinnati Medical Center, Cincinnati, OH 45267
-
Closed to Enrollment
Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, OH 44106
-
Closed to Enrollment
Oklahoma
Oklahoma Cystic Fibrosis Center, OKC, OK 73104
-
Closed to Enrollment
Oregon
Oregon Health Sciences University, Portland, OR 97239
-
Closed to Enrollment
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, PA 15224
-
Closed to Enrollment
South Carolina
Medical University of South Carolina, Charleston, SC 29425
-
Closed to Enrollment
Texas
Baylor College of Medicine, Houston, TX 77030
-
Closed to Enrollment
Virginia
University of Virginia, Charlottesville, VA 22908
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
The participants for Cohort 1 must have an FEV1 of 60% or lower at the screening visit. The participants for Cohort 2 must have an FEV1 of 60% or greater at the screening visit.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More